Welcome to our dedicated page for Trevi Therapeutics SEC filings (Ticker: TRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Trevi Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Trevi Therapeutics's regulatory disclosures and financial reporting.
Trevi Therapeutics reported that investment manager FMR LLC, together with Abigail P. Johnson, has filed a Schedule 13G showing beneficial ownership of 6,500,009.33 shares of Trevi common stock, representing 5.1% of the class as of 12/31/2025.
FMR LLC has sole voting power over 6,485,775 shares and sole dispositive power over the full 6,500,009.33 shares, with no shared voting or dispositive power. The securities were acquired and are held in the ordinary course of business, and not with the purpose or effect of changing or influencing control of Trevi.
The Vanguard Group has filed a Schedule 13G reporting beneficial ownership of 6,434,655 shares of Trevi Therapeutics common stock, representing 5.01% of the class. Vanguard reports shared voting power over 833,386 shares and shared dispositive power over all 6,434,655 shares.
The holdings are described as being acquired and held in the ordinary course of business, not to change or influence control of Trevi. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report beneficial ownership on a disaggregated basis.
Trevi Therapeutics reported that its Chief Financial Officer, David C. Hastings, received a grant of stock options on January 8, 2026. The award covers 375,000 stock options to purchase common stock at an exercise price of $11.21 per share. According to the vesting schedule, 25% of the underlying 375,000 shares vest on January 8, 2027, with the remaining 75% vesting in equal monthly installments through January 8, 2030. After this grant, Hastings beneficially owns 375,000 derivative securities directly in the form of these options.
Trevi Therapeutics, Inc. executive David C. Hastings, the company’s Chief Financial Officer, filed an initial Form 3 ownership report as of 01/08/2026.
The filing indicates that he has no securities beneficially owned in Trevi Therapeutics, with both the non-derivative and derivative securities tables showing no holdings. A power of attorney (Exhibit 24.1) authorizes attorney-in-fact Christopher Galletta to sign the form on his behalf.
Trevi Therapeutics (TRVI) filed its Q3 2025 10‑Q, reporting a net loss of $11.8 million (basic and diluted $(0.08) per share) versus $13.2 million (($(0.13)) a year ago. Operating expenses were $13.9 million, comprised of $10.1 million in R&D and $3.8 million in G&A. Interest income contributed $2.1 million in the quarter.
For the nine months, net loss was $34.4 million. The balance sheet strengthened: cash and cash equivalents $56.9 million and marketable securities $138.1 million at September 30, 2025, supporting total current assets $198.3 million. Stockholders’ equity was $189.8 million and total liabilities were $9.6 million.
Year‑to‑date financing cash inflows were $120.7 million, including $108.2 million from a June 2025 underwritten offering and $10.8 million from warrant exercises. Shares outstanding were 128,215,113 at September 30, 2025; 128,230,134 were outstanding as of October 31, 2025.
Trevi Therapeutics (TRVI) announced financial results for the quarter ended September 30, 2025, and furnished a detailed press release as Exhibit 99.1. The disclosure under Item 2.02 is furnished, not filed, and is not subject to Section 18 liability or incorporated by reference unless specifically referenced.
Trevi Therapeutics, Inc. (TRVI) submitted a Form 144 notice indicating a proposed sale of 108,650 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $1,032,175.00. The proposed approximate sale date is 10/07/2025, and the shares trade on Nasdaq. The filing shows these shares were acquired by an option exercise on 02/26/2023, originally representing 312,855 shares from that exercise.
The filer also reported equity sales totaling 341,505 shares in the prior three months, generating gross proceeds of approximately $2,863,024.00 across multiple dates from 08/27/2025 to 10/06/2025. The shares outstanding figure listed is 121,776,855, making the proposed sale roughly 0.09% of outstanding stock. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Trevi Therapeutics, Inc. submitted a Form 144 disclosing a proposed sale of 40,000 shares of common stock through Stifel Nicolaus & Company with an aggregate market value of $386,716, expected on 10/03/2025. The filing reports 121,776,855 shares outstanding. The securities being sold were originally acquired via an option exercise on 02/26/2023 totaling 312,855 shares with a reported payment date of 02/16/2023. The filer also disclosed recent open-market sales by Lisa Delfini totaling 312,855 shares during Aug–Sep 2025, including a 155,000-share sale on 09/09/2025 that generated $1,256,787.
Trevi Therapeutics (TRVI) filed a Form 144 reporting a proposed sale of common stock through Stifel Nicolaus & Company. The notice lists 312,855 shares to be sold with an aggregate market value of $2,532,530, against total shares outstanding of 121,776,855. The approximate date of sale is 08/27/2025 and the securities exchange is Nasdaq.
The filing discloses how the shares were acquired: 65,712 shares from restricted stock units dated 02/15/2023 (paid 02/16/2023 in cash) and 259,576 shares from an option exercise dated 02/26/2023 (paid 02/16/2023 in cash). No securities were reported sold by the person in the past three months. The filer signs the standard representation that they do not possess nonpublic material adverse information about the issuer.
Trevi Therapeutics reports that Chief Financial Officer Lisa Delfini will end her employment and resign as CFO on August 22, 2025. The company states that her resignation is not due to any disagreement over operations, policies, or practices. In line with its Executive Separation Benefits and Retention Plan, Trevi has agreed to provide her with separation benefits, conditioned on signing a severance and release agreement that includes a general release of claims, a non-disparagement commitment, and reaffirmation of existing confidentiality, non-solicitation, and non-compete obligations.
As of the effective date of her departure, President and Chief Executive Officer Jennifer L. Good will also serve as the company’s principal financial officer on an interim basis until a new principal financial officer is designated.